Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas
NCT04617002 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS
Last updated 2025-08-20
Summary
This is an intermediate-size expanded access protocol to provide ONC201 (dordaviprone) to patients with H3 K27M-mutant and/or midline gliomas who cannot access ONC201 (dordaviprone) through clinical trials.
Conditions
- Glioma
- H3 K27M
Interventions
- DRUG
-
ONC201 (dordaviprone)
ONC201 (dordaviprone) is a ClpP agonist and DRD2 antagonist.
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 0 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
NCT07301268 ·Status: RECRUITING ·Phase: PHASE2
-
First in Patient Study for PF-06840003 in Malignant Gliomas
NCT02764151 ·Status: TERMINATED ·Phase: PHASE1
-
Implantable Microdevice In Primary Brain Tumors
NCT04135807 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
NCT06838676 ·Status: RECRUITING ·Phase: PHASE2
-
Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)
NCT05630209 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Patient's Derived Organoids for Drug Screening in Glioblastoma
NCT06781372 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma
NCT03739372 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations
NCT05267106 ·Status: TERMINATED ·Phase: PHASE2
-
131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma
NCT05063357 ·Status: WITHDRAWN ·Phase: PHASE1
-
Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG).
NCT01688401 ·Status: COMPLETED ·Phase: PHASE1
-
Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy
NCT01502917 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme
NCT00635557 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Phase 2 Study of BGJ398 in Patients With Recurrent GBM
NCT01975701 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
NCT03871257 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
NCT03830151 ·Status: RECRUITING ·Phase: PHASE1
-
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
NCT02359565 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma
NCT03893903 ·Status: COMPLETED ·Phase: PHASE1
-
Study of MT027 in Patients with Recurrent or Progressive High-grade Glioma
NCT06737146 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption in GBM Patients
NCT04998864 ·Status: COMPLETED
-
Feasibility of Intraoperative Microdialysis During Neurosurgery for Central Nervous System Malignancies
NCT04047264 ·Status: RECRUITING ·Phase: NA
-
Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)
NCT02108002 ·Status: COMPLETED ·Phase: PHASE1
-
Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
NCT01644773 ·Status: COMPLETED ·Phase: PHASE1
-
O(6)-Benzylguanine in Treating Patients With Malignant Glioma
NCT00002971 ·Status: COMPLETED ·Phase: PHASE1
-
Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy
NCT04417088 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Targeted Pediatric High-Grade Glioma Therapy
NCT05839379 ·Status: RECRUITING